Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Humacyte, Inc. announced FDA acceptance of its Investigational New Drug application to begin a Phase 2a clinical study evaluating its Coronary Tissue Engineered Vessel (CTEV) as an off-the-shelf alternative for coronary artery bypass grafting (CABG). This marks a significant advancement in coronary artery disease treatment, offering potential impro…